In September 2020, the first virtual TIDES: Oligonucleotide and Peptide Therapeutics conference took place, delivering over 175 presentations and discussions exploring a diverse range of topics across the spectrum of oligonucleotide and peptide therapeutics.
This year's agenda included topics including preclinical, CMC and drug delivery strategies, COVID-19 and pandemic responses, while also sporting a brand new stream on partnering in the industry.
We’ve put together a report, providing a summary of the key themes, highlights and hottest topics across live keynotes, panel discussions on-demand presentations and posters.
The report features:
- Key Themes of The Event - Executive Summary - Biotech researcher and writer Dr. Catarina Carrao reflects on the main themes of the event, explored through top keynotes and panel sessions, in this executive summary.
- Top Keynote Presentation: Tuning siRNA Potency, Specificity and Distribution through Chemistry - Prof. Anastasia Khvorova, Professor at University of Massachusetts Medical School detailed the methods of optimizing siRNAs within the chemistry process in a keynote session and Q&A.
- Hot Topic Keynote Presentation: mRNA as Medicine - In an exciting keynote, Dr. Melissa Moore, Chief Scientific Officer, Moderna Therapeutics, Inc. revealed the latest uses of messenger RNA in drug and vaccine development.
- Poster: A Universal Method for the Quantitation of Multiple Oligonucleotides from Plasma by MFLC-MS/MS - This popular poster and presentation by Chad Christianson, Senior Principal Scientist at Alturas Analytics, describes a method of bioanalysis of oligonucleotides which shows numerous benefits over ELISA and qPCR.
- On-demand Session: Oligonucleotide Manufacturing Capabilities at Ajinomoto Bio-Pharma Services - Soichi Utsumi, General Manager of Sales at Aji Bio-Pharma Osaka, introduced the leading oligo capabilities and novel technologies at Ajinomoto Bio-Pharma.
- On-demand Session: An Approach to Process Validation for Peptides: Applying Bachem CMC concept to (Nle3)-Angiotensin I/II validation, a case study - Matteo Villain, Ph.D., Vice President, CMC Development at Bachem Americas, Inc. describes the company's approach to Process Design and Process Qualification of peptidic API as demonstrated in a case study for (Nle3)-Angiotensin I/II validation.
Whether you attended the event, or you'd just like to find out more, we invite you to join us as we look back at the best parts of the week.